Emergent BioSolutions | EBS - Current Assets


Emergent BioSolutions reported $679.5M in Current Assets for its fiscal quarter ending in December of 2023.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
ANI Pharmaceuticals USD 747.08M 6.03M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Exelixis USD 1.21B 234.65M Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Myriad Genetics USD 312.8M 19.8M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025